Search

Author/Creator Chan, Gary

62. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Issue 6 (16th February 2017)

Authors:
Panés, Julian; Sandborn, William J; Schreiber, Stefan; Sands, Bruce E; Vermeire, Séverine; D'Haens, Geert; Panaccione, Remo; Higgins, Peter D R; Colombel, Jean-Frederic; Feagan, Brian G; Chan, Gary; Moscariello, Michele; Wang, Wenjin; Niezychowski, Wojciech; Marren, Amy; Healey, Paul; Maller, Eric
Journal:
Gut
Issue:
Volume 66:Issue 6(2017)
Page Start:
1049
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

63. Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the UC Clinical Program: 705. (October 2019)

Authors:
Lichtenstein, Gary R.; Ciorba, Matthew A.; Rogler, Gerhard; Quirk, Daniel; Thorpe, Andrew J.; Pedersen, Ronald D.; Lawendy, Nervin; Chan, Gary; Panés, Julian
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

64. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. (27th November 2020)

Authors:
Winthrop, Kevin L; Loftus, Edward V; Baumgart, Daniel C; Reinisch, Walter; Nduaka, Chudy I; Lawendy, Nervin; Chan, Gary; Mundayat, Rajiv; Friedman, Gary S; Salese, Leonardo; Thorpe, Andrew J; Su, Chinyu
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15:Number 6(2021)
Page Start:
914
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

65. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program: 726. (October 2019)

Authors:
Winthrop, Kevin L.; Loftus, Edward V.; Baumgart, Daniel C.; Salese, Leonardo; Thorpe, Andrew J.; Lawendy, Nervin; Chan, Gary; Pedersen, Ronald D.; Reinisch, Walter
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

66. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. Issue 2 (1st February 2022)

Authors:
Sands, Bruce E; Long, Millie D; Reinisch, Walter; Panés, Julian; Loftus, Edward V; Nduaka, Chudy I; Soonasra, Arif; Mundayat, Rajiv; Lawendy, Nervin; Chan, Gary; Friedman, Gary S; Su, Chinyu
Journal:
Inflammatory bowel diseases
Issue:
Volume 28:Issue 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

67. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. Issue 2 (20th March 2021)

Authors:
Sands, Bruce E; Long, Millie D; Reinisch, Walter; Panés, Julian; Loftus, Edward V; Nduaka, Chudy I; Soonasra, Arif; Mundayat, Rajiv; Lawendy, Nervin; Chan, Gary; Friedman, Gary S; Su, Chinyu
Journal:
Inflammatory bowel diseases
Issue:
Volume 28:Issue 2(2022)
Page Start:
234
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

68. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Issue 9 (19th August 2021)

Authors:
Curtis, Jeffrey R; Regueiro, Miguel; Yun, Huifeng; Su, Chinyu; DiBonaventura, Marco; Lawendy, Nervin; Nduaka, Chudy I; Koram, Nana; Cappelleri, Joseph C; Chan, Gary; Modesto, Irene; Lichtenstein, Gary R
Journal:
Inflammatory bowel diseases
Issue:
Volume 27:Issue 9(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

69. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Issue 9 (16th December 2020)

Authors:
Curtis, Jeffrey R; Regueiro, Miguel; Yun, Huifeng; Su, Chinyu; DiBonaventura, Marco; Lawendy, Nervin; Nduaka, Chudy I; Koram, Nana; Cappelleri, Joseph C; Chan, Gary; Modesto, Irene; Lichtenstein, Gary R
Journal:
Inflammatory bowel diseases
Issue:
Volume 27:Issue 9(2021)
Page Start:
1394
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

70. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open‐Label, Long‐Term Extension Study With up to 5.5 Years of Treatment: 704. (October 2019)

Authors:
Lichtenstein, Gary R.; Loftus, Edward V.; Soonasra, Arif; Lawendy, Nervin; Chan, Gary; Zhang, Haiying; Wang, Wenjin; Thorpe, Andrew J.; Bloom, Stuart
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗